TransMolecular, Inc. Presentation at ARVO 2009
April 30, 2009
TransMolecular, Inc. announced that new information on the anti-angiogenic method-of-action of TM601 will be presented at ARVO. TM601 is a novel, wholly synthetic peptide found to have robust anti-angiogenic activity in neovascular diseases, including ophthalmic disease and cancer.
Poster # 1164/D1126 is titled, “TM601, a Peptide That Binds Annexin A2, Causes Regression of Choroidal Neovascularization (CNV),”
TM601 is a novel, wholly synthetic peptide found to have robust anti-angiogenic activity in neovascular diseases, including cancer and ophthalmic disease. Most recently, the effects of TM601 on the neovasculature have also been validated in animal models of ophthalmic disease, including wet age-related macular degeneration (AMD).
Read the full release.
- An Overview of Current Anti-VEGF Protocols for AMD
- Will 2012 be the Year for Gene Therapy in Ophthalmology?
- Is Anti-Pericyte Aptamer Effective Against CNV?
- Advanced Cell Technology, OHSU Researchers Show Safety, Efficacy of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigment Epithelium (RPE)
- Adjunctive Therapy for Intravitreal Injections for ARMD
Comments
Jump down to form below to submit your own comments
